Form D · Other Health Care
Prevail Therapeutics Inc.
New York, NY · CIK 0001714798
Offering snapshot reported Mar 14, 2018 · SEC filing
- Reported sold
- $57M Offering amount: $65M
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 7, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 14, 2018 | Initial | $57,000,049 | No comparison | 15 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-307751
Source: Form D, filed Mar 14, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Asa Abeliovich | Director, Executive |
| Mona Ashiya | Director |
| Carl Gordon | Director |
| Peter Thompson | Director |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
430 East 29 Th Street, Suite 940
New York, NY, 10016
New York, NY, 10016